Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Methamphetamine-dependence, Methamphetamine Abuse
In brief
This Phase 2 study will evaluate the safety and efficacy of monthly intravenous doses of IXT-m200 in treatment-seeking individuals with methamphetamine (METH) use disorder. The hypothesis are that following an initial relapse, IXT-m200 will reduce the occurrence of stimulant-positive saliva samples compared to placebo and improve the signs and symptoms of METH Use Disorder (MUD).
Key facts
- Study ID
- NCT05034874
- Run by
- InterveXion Therapeutics, LLC
- People needed
- 61
- Starts
- 2022-06-09
- Expected to finish
- 2023-11-07
- Last updated by the study team
- 2024-10-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pillar Clinical Research — Bentonville, Arkansas, United States
- Woodlands International Research Group — Little Rock, Arkansas, United States
- Artemis Institute for Clinical Research — San Diego, California, United States
- Pillar Clinical Research — Lincolnwood, Illinois, United States
- Midwest Clinical Research Center — Dayton, Ohio, United States
- InSite Clinical Research — DeSoto, Texas, United States
- HD Research — Houston, Texas, United States
- Pillar Clinical Research — Richardson, Texas, United States
- Alpine Research — Clinton, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.